Apart from these and other well-characterised alterations in AS patterns affecting key components of cancer hallmarks, such as PT53, hTERT, EGFR, CD44, KLF6, FAM3B, MENA, NUMB, or BRAF, which have been extensively reviewed before (David and Manley 2010; Bonomi et al. 2013; Oltean and Bates 2014; Sveen et al. 2016), novel insights into tumour-associated dysregulation of splicing and its biological consequences have been recently described. This evidence concerns the gene EGFR and cancer.